Skip to main content
HR 937 116th Congress House

Right Rebate Act of 2019

Official title: To amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.

Introduced: January 31, 2019 See on congress.gov
Health Business recordsCivil actions and liabilityHome and outpatient careInflation and prices
More subjectsShow fewer subjects
MedicaidPrescription drugsState and local government operations
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 31, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 31, 2019
Referred to the Subcommittee on Health.
Jan 31, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action January 31, 2019

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Plain-English summary Congressional Research Service

Right Rebate Act of 2019

This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

 Related & companion bills 2
  • HR 1839 Related bill Medicaid Services Investment and Accountability Act of 2019
  • S 205 Related bill Right Rebate Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Democratic 1
D
Welch, Peter
Vermont · Jan 31, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 937: Right Rebate Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-937/
MLA
"H.R. 937: Right Rebate Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-937/.
Bluebook (legal)
H.R. 937, 116th Cong. (2026), https://openamerica.io/bill/116-HR-937/.
Markdown link
[H.R. 937: Right Rebate Act of 2019](https://openamerica.io/bill/116-HR-937/)
Report a problem